Skip to content

Erasca, Inc. ERAS Change in AP

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Eli Lilly logo
Eli LillyLLY
$2.55B+290%
Pfizer logo
PfizerPFE
-$117.25M+54.2%
Amgen logo
AmgenAMGN
$571M+14.9%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$16.86M+304%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.79M+9.5%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s change in AP?
Erasca, Inc. (ERAS) reported change in AP of $1.18M in Q1 2026.
How has Erasca, Inc.'s change in AP changed year-over-year?
Erasca, Inc.'s change in AP decreased by 34.1% year-over-year, from $1.79M to $1.18M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.